CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Cost of product revenue	$ 613,000	$ 617,000	$ 1,524,000	$ 1,864,000
Research and development	5,940,000	3,312,000	13,336,000	9,597,000
Sales and marketing	2,109,000	2,261,000	7,089,000	6,596,000
General and administrative	4,384,000	3,969,000	14,876,000	12,450,000
Series 3 warrants inducement expense				1,462,000
ELOC warrants inducement expense				172,000
Total operating expenses	13,046,000	10,159,000	36,825,000	32,141,000
Loss from operations	(9,896,000)	(9,529,000)	(28,129,000)	(29,886,000)
Interest expense	(2,731,000)	(2,078,000)	(10,089,000)	(5,988,000)
Loss on extinguishment of debt			(2,187,000)	(753,000)
Change in fair value of financial instruments and hybrid instrument designated at Fair Value Option	176,000	(565,000)	652,000	(1,639,000)
Other expense, net	(158,000)	(20,000)	(410,000)	(16,000)
Loss before income tax	(12,609,000)	(12,192,000)	(40,163,000)	(38,282,000)
Income tax expense
Net loss and comprehensive loss	(12,609,000)	(12,192,000)	(40,163,000)	(38,282,000)
Net loss attributable to noncontrolling interest	(89,000)		(290,000)
Net loss attributable to common shareholders	(12,520,000)	(12,192,000)	(39,873,000)	(38,282,000)
Net loss attributable to common shareholders (diluted)	$ (12,520,000)	$ (12,192,000)	$ (39,873,000)	$ (38,282,000)
Net loss per share, basic	$ (0.12)	$ (0.27)	$ (0.49)	$ (0.87)
Net loss per share, diluted	$ (0.12)	$ (0.27)	$ (0.49)	$ (0.87)
Weighted-average common shares outstanding, basic	106,362,178	45,840,262	81,657,061	44,167,885
Weighted-average common shares outstanding, diluted	106,362,178	45,840,262	81,657,061	44,167,885
Product revenue
Revenue
Total revenue	$ 3,150,000	$ 630,000	$ 8,696,000	$ 2,255,000